Our politicians and health technology institutions invite this comparison, and the obvious question, given that the latter consistently invokes opportunity cost to justify rejecting funding for innovative medicines. Opportunity cost is not just an economic consideration. It is a moral and ethical question when the powerful are preferenced over patients. …
Opportunity cost is a moral and ethical question when it involves travel, tickets, or treating sick children
December 11, 2025 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Cartherics and Catalent deepen partnership to accelerate next generation cell therapies
April 10, 2026 - - Australian Biotech -
Lower official co-payment but patients paying for more unsubsidised medicines
April 10, 2026 - - Latest News -
The 'Dispatched' Week in Review Podcast - 10 April
April 10, 2026 - - Podcast -
Is there any example of another review or inquiry taking this long?
April 10, 2026 - - Latest News -
Rewriting the rules of PBS negotiations to deliver a patient-first reset
April 10, 2026 - - Latest News -
A decade of readiness as AVITA medical expands burn response capability
April 9, 2026 - - Australian Biotech -
Moderna names Carolyn Tucek-Szabo to lead Australia and New Zealand operations
April 9, 2026 - - Latest News